FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis
Status: | Terminated |
---|---|
Conditions: | Ocular |
Therapuetic Areas: | Ophthalmology |
Healthy: | No |
Age Range: | 3 - Any |
Updated: | 4/21/2016 |
Start Date: | June 2009 |
End Date: | June 2010 |
The objective of this study is to evaluate the efficacy of FST-100 (0.1% dexamethasone)
Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.
Ophthalmic Suspension in the treatment of suspected acute adenoviral conjunctivitis.
Inclusion Criteria:
- Conjunctivitis within seven (7) days of initial ocular symptoms of redness and/or
discharge.
- Clinical suspicion of adenoviral etiology.
- At least three (3) years of age.
- Subjects or their guardians capable of understanding the purpose and risks of the
study, and able to give informed consent.
- Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute
conjunctivitis:
1. conjunctival injection/inflammation, and
2. conjunctival discharge/exudates.
Exclusion Criteria:
- Conjunctivitis longer than 7 days after initial ocular symptoms.
- Corneal ulcer, endophthalmitis, or any other confounding infection of the eye.
- Patients taking ocular anti-inflammatory medications on a chronic basis.
- Active herpes ocular infection.
- Known or suspected pregnancy.
- Known allergy to PVP-I.
- Known allergy to dexamethasone.
- Patients with a history of elevation in intraocular pressure as a result of steroid
use ("steroid responders".
We found this trial at
13
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials